# Tissue Resources Shared Resource

> **NIH NIH P30** · CASE WESTERN RESERVE UNIVERSITY · 2021 · $181,843

## Abstract

TRANSGENIC AND TARGETING SHARED RESOURCE
PROJECT SUMMARY/ABSTRACT
The Transgenic and Targeting Shared Resource (Transgenic SR) is an essential asset to Case Comprehensive
Cancer Center (Case CCC) members' research, illustrated by the breadth of scientific program involvement and
reflected in the large number of investigators who use this SR. Last year alone, 45 investigators, 40% of whom
were Case CCC members, accounting for 39% of total usage, from 5 out of 7 of the Center’s programs used the
SR. The Transgenic SR makes transgenic, chimeric, knockout, and knock-in mice and provides services in
rederivation, cryopreservation, reanimation, in vitro fertilization and surgery. Central to the success of
investigators with new mouse genetic models is the role this facility plays in consultation, education and training,
as well as support after service. The Specific Aims of the Transgenic SR are to:
 1. Provide Case CCC members with consultation, education and training. The Director of the Transgenic
 SR consults with Cancer Center members and their research staff to ensure they utilize the best
 technology to meet their experimental goals. The rapid evolution of CRISPR/Cas9 technologies makes
 consultation particularly important.
 2. Provide Case CCC members with new mouse genetic models. The Transgenic SR generates the genetic
 variants of mice in a timely and cost-effective manner.
 3. Provide Case CCC members with follow-up support through direct interaction and through the wealth of
 information available on the facility website.
At last review, the Transgenic SR was rated Outstanding Merit. Throughout the current funding cycle (2012-
2016), the Transgenic SR provided services to 133 registered users, 41 (31%) of whom are Case CCC
members, representing 5 of the Center’s 7 Programs.
The Transgenic SR has had great success in gene targeting using CRISPR/Cas9. Since 2014, the SR has
successfully completed over 30 new gene-targeted mutations in mice using this approach, the vast majority of
which have been disease-causing missense mutations. The Transgenic SR is in the vanguard of transgenic
cores in applying CRISPR/Cas9 technology. In the last funding period, the Transgenic SR assisted Case CCC
members in: generating mice that model human mutations leading to cancer; identifying cancer susceptibility
loci; generating mice for in vivo imaging of tumors; and investigating the basic biology of genes implicated in
cancer. This SR is the only transgenic core in the Cleveland area, and it serves investigators throughout the
region. As a consequence, it is strongly supported by CWRU. All Case CCC members have access to this jointly
managed SR.

## Key facts

- **NIH application ID:** 10135941
- **Project number:** 5P30CA043703-31
- **Recipient organization:** CASE WESTERN RESERVE UNIVERSITY
- **Principal Investigator:** Marta Couce
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $181,843
- **Award type:** 5
- **Project period:** 1997-08-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10135941

## Citation

> US National Institutes of Health, RePORTER application 10135941, Tissue Resources Shared Resource (5P30CA043703-31). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10135941. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*